<DOC>
	<DOCNO>NCT00942617</DOCNO>
	<brief_summary>Aspirin show reduce cardiovascular event risk individual . Elucidation mechanism aspirin resistance possible loss effect aspirin time chronic aspirin treatment necessitate precise method measure `` release phase '' platelet activation , include release dense granule platelet .</brief_summary>
	<brief_title>Measurement Platelet Dense Granule Release Healthy Volunteers</brief_title>
	<detailed_description>This proposal pilot study evaluate feasibility measure 5-hydroxytryptamine ( 5-HT ) release platelet indicator dense granule release platelet activation volunteer take aspirin . One phase platelet response activate agonist involve release dense granule , know contain 5HT ( serotonin ) ATP . There various method measure degranulation platelet : ATP release measure use lumiaggregometer , release 14C radiolabeled 5-HT platelet . Using aggregometer 14C label 5-HT assay use measure 5-HT release platelet . Our experience suggest ADP-induced ATP release insensitive detect low level platelet dense granule release , occur aspirin-treated subject . The pilot study permit optimize method reliably detect low level 5HT release patient achieve submaximal inhibition cyclooxygenase aspirin treatment .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Males age 18 Nonsmokers No chronic medical illness No chronic medication ASA/NSAID use previous 14 day . History chronic NSAID use . Currently take NSAIDs , opioid analgesic , corticosteroid , anticoagulant . History coronary artery disease , myocardial infarction , coronary artery bypass grafting , percutaneous angioplasty , diabetes mellitus stroke . History hypertension BMI &gt; 35 Smokers History gastric , duodenal , esophageal ulcer serious gastrointestinal bleed . History frequent headache , pain syndrome , condition require frequent use analgesic . History adverse reaction ASA . Initial platelet count &lt; 100K/µl &gt; 500K/µl . Initial hematocrit &lt; 35 % &gt; 50 % . Weight le 110 pound . Female subject exclude avoid possible confound uterine smooth muscle production prostaglandins various throughout menstrual cycle .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>platelet aggregation</keyword>
	<keyword>granule secretion</keyword>
	<keyword>thromboxane production</keyword>
	<keyword>cyclooxygenase-1</keyword>
	<keyword>ATP release</keyword>
	<keyword>aspirin resistance</keyword>
	<keyword>platelet activation</keyword>
	<keyword>flow cytometry</keyword>
	<keyword>Platelet aggregation healthy volunteer</keyword>
</DOC>